cryptotanshinone

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: cryptotanshinone
• 英文别名: 2,6,6-trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione；2,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione
• 化学式: C₁₉H₂₀O₃
• 分子量: 296.366
• InChiKey: CAHVBEASHABWEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE
  申请人：Kwak Taehwan

  公开号：US20100239674A1

  公开（公告）日：2010-09-23

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种用于治疗和/或预防勃起功能障碍的药物组合物，包括（a）按照式1或式2表示的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME
  申请人：Yoo Sang-Ku

  公开号：US20100137422A1

  公开（公告）日：2010-06-03

  Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种用于治疗和/或预防涉及代谢综合征的疾病的制药组合物，包括(a)根据规范中定义的公式1所代表的特定化合物的治疗有效量，或其异构体，前药或溶剂或其任意组合物，以及(b)药学上可接受的载体，稀释剂或赋形剂，或其任意组合物。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS
  申请人：Kwak Taehwan

  公开号：US20100255054A1

  公开（公告）日：2010-10-07

  Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种药物组合物，用于治疗和/或预防再狭窄，包括(a) 一定量的化合物，其化学式为1和2，或其药学上可接受的盐、前药、溶剂或异构体，且具有治疗效果，以及(b) 药学上可接受的载体、稀释剂或赋形剂，或任何其组合。
• METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION
  申请人：KWAK Taehwan

  公开号：US20120114714A1

  公开（公告）日：2012-05-10

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种治疗和/或预防勃起功能障碍的药物组合物，包括（a）公式1或2所代表的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂或其组合。
• PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND
  申请人：Jo In Geun

  公开号：US20100209513A1

  公开（公告）日：2010-08-19

  Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound.